945-24-4

Basic information

• Product Name: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE
• Synonyms: AKOS 213-118;(2,4-DIAMINO-PTERIDIN-6-YL)-METHANOL;(2,4-DIAMINO-6-PTERIDINYL)METHANOL;2,4-DIAMINO-6-PTERIDINEMETHANOL;2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE;2,4-diaminopteridine-6-ylmethanol;2,4-Diamino-6-hydroxymethylpteridine hydrochloride or HBR;2,4-DIAMINO-6-HYDROXYMETHYLPTERIDINE, 95 %
• CAS NO: 945-24-4
• Molecular Formula: C₇H₈N₆O
• Molecular Weight: 192.18
• EINECS: 213-412-2
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Heterocycles;Aromatics Compounds;Aromatics;Bases & Related Reagents;Inhibitors;Nucleotides
• Mol File: 945-24-4.mol
• Article Data: 17

Chemical Properties

• Melting Point: 333-334 °C (decomp)
• Boiling Point: 560.2 °C at 760 mmHg
• Flash Point: 292.6 °C
• Appearance: /
• Density: 1.673g/cm³
• Storage Temp.: 2-8°C
• PKA: 12.00±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE(945-24-4)
• EPA Substance Registry System: 2,4-DIAMINO-6-(HYDROXYMETHYL)PTERIDINE(945-24-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 945-24-4(Hazardous Substances Data)

Usage

Uses

2,4-Pteridinediamine-6-methanol (Methotrexate EP Impurity A) is an impurity of Methotrexate. A useful reagent for the development of selective antiparasitic compounds.

InChI:InChI=1/C7H8N6O/c8-5-4-6(13-7(9)12-5)10-1-3(2-14)11-4/h1,14H,2H2,(H4,8,9,10,12,13)

Upstream product

• 52-89-1 l-cysteine hydrochloride 
• 5392-28-9 2,4,5,6-tetraaminopyrimidine sulfate 
• 96-26-4 dihydroxyacetone 
• 10318-18-0 DL-cysteine hydrochloride 
• 39944-62-2 2,4,5,6-tetraamino-pyrimidine dihydrochloride 
• 191786-02-4 N-{2-Butyrylamino-6-[(E)-2-(4-ethyl-phenyl)-vinyl]-pteridin-4-yl}-butyramide 
• 191786-03-5 N-(2-Butyrylamino-6-formyl-pteridin-4-yl)-butyramide 
• 191786-01-3 β-(2,4-diamino-6-pteridinyl)-p-ethylstyrene 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 32363-58-9 N-{6-[(acetyloxy)methyl]-3,4-dihydro-4-oxopteridin-2-yl}acetamide 
• 712-29-8 6-(hydroxymethyl)pterin 
• 522614-11-5 N-{[(acetyloxy)methyl]-4-[2-(4-nitrophenyl)ethoxy]pteridin-2-yl}acetamide 
• 59-05-2 N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid 
• 1004-74-6 2,4,5,6-tetraaminopyrimidine 

Downstream Products

• 59368-16-0 6-bromomethyl-pteridine-2,4-diamine 
• 19741-14-1 4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoic acid 
• 79640-70-3 (S)-5-(tert-butoxy)-4-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-5-oxopentanoic acid 
• 23853-09-0 4-[(2,4-diaminopteridin-6-ylmethyl)-N-methylamino]benzoic acid methyl ester 
• 54-62-6 aminopterin 
• 95484-99-4 α-methyl γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-formylpteroyl)-L-glutamate 
• 95485-00-0 γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-formylpteroyl)-L-glutamate 
• 95484-98-3 γ-tert-butyl N-(4-amino-4-deoxypteroyl)-L-glutamate 
• 95485-01-1 p-nitrophenyl 4-amino-4-deoxy-N¹⁰-formylpteroate 
• 79640-68-9 α-methyl γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-L-glutamate 
• 79640-76-9 γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-L-glutamate 
• 89043-75-4 4-amino-4-deoxy-N¹⁰-formylpteroic acid 
• 36093-85-3 4-amino>benzoic acid 
• 43111-51-9 ethyl 4-amino-4-deoxy-N¹⁰-methylpteroate 

Relevant articles and documents

ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE

The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or an ethylene glycol-containing moiety; and (ii) a ligand of the formula D-L1-Z-L2, wherein D comprises an antifolate drug or folic acid, L1 comprises a first linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, L2 comprises a second linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, wherein L1 and L2 may be the same or different, and wherein Z represents a carbonyl-containing group linking L1 and L2, and wherein L2 is coupled to said core, Also provided are pharmaceutical compositions comprising such nanoparticles, medical uses thereof and methods for producing the nanoparticles.

Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis

A series of novel hydrogen peroxide sensitive prodrugs of methotrexate (MTX) and aminopterin (AMT) were synthesized and evaluated for therapeutic efficacy in mice with collagen induced arthritis (CIA) as a model of chronic rheumatoid arthritis (RA). The prodrug strategy selected is based on ROS-labile 4-methylphenylboronic acid promoieties linked to the drugs via a carbamate linkage or a direct C-N bond. Activation under pathophysiological concentrations of H2O2 proved to be effective, and prodrug candidates were selected in agreement with relevant in vitro physicochemical and pharmacokinetic assays. Selected candidates showed moderate to good solubility, high chemical and enzymatic stability, and therapeutic efficacy comparable to the parent drugs in the CIA model. Importantly, the prodrugs displayed the expected safer toxicity profile and increased therapeutic window compared to MTX and AMT while maintaining a comparable therapeutic efficacy, which is highly encouraging for future use in RA patients.

DIAMINOPTERIDINE DERIVATIVES

The present invention relates novel diaminopteridine derivatives, their compositions and method of treatment comprising the same for use as anti-infectives.